Alopecia areata as an immune-related adverse event associated with response to immune checkpoint inhibitors
Eur J Dermatol
.
2022 Jul 1;32(4):546-548.
doi: 10.1684/ejd.2022.4315.
Authors
Rika Suzuki
1
,
Yukiko Kiniwa
1
,
Toshikazu Omodaka
1
,
Shiho Katsuie
1
,
Tatsuya Nihei
1
,
Ai Sato
2
,
Yuko Takazawa
1
,
Ryuhei Okuyama
1
Affiliations
1
Department of Dermatology, Shinshu University School of Medicine, Matsumoto, Japan
2
Department of Diabetes, Endocrinology and Metabolism, Shinshu University School of Medicine, Matsumoto, Japan
PMID:
36301769
PMCID:
PMC10214311
DOI:
10.1684/ejd.2022.4315
No abstract available
MeSH terms
Alopecia Areata* / chemically induced
Alopecia Areata* / drug therapy
Humans
Immune Checkpoint Inhibitors / adverse effects
Substances
Immune Checkpoint Inhibitors
Supplementary concepts
Diffuse alopecia